Recent Updates
Recently added Catalysts

Fetal porcine cells, Neurocell-PD

Phase 2

Parkinson's Disease | Small molecule | Neurology |Sanofi|Last Updated: Mar 18, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

Fetal porcine cells, Neurocell-PD · 1 trial · 1 indication

Phase 2 1
NCT00226460Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.Parkinson's Disease
COMPLETED- Analytics
PHASE2COMPLETED
Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.
Parkinson's DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

change in UPDRS

Secondary Endpoints

change in PET scan
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSINGLE_GROUP
PurposeTREATMENT

Interventions

NameTypeDescription
Fetal porcine cells, Neurocell-PDDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * The patient has idiopathic Parkinson's disease. a) with bradykinesia and either rest tremor or rigidity, b) history of asymmetry of Parkinson's disease signs, c) history of progression of Parkinson's disease signs, d) no other suspected cause of Parkinson's disease, e) the pat...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Fetal porcine cells, Neurocell-PD

What is Neurocell-PD used for?

Neurocell-PD is an investigational cell therapy being studied for the treatment of Parkinson's Disease. It consists of fetal porcine cells that are transplanted into patients. The therapy is currently in clinical development and has not been approved by regulatory authorities.

What does Neurocell-PD target?

Neurocell-PD is a cell therapy that uses fetal porcine cells, which are intended to replace or support the function of dopamine-producing neurons in the brain. This approach aims to address the underlying cell loss associated with Parkinson's Disease.

Who is developing Neurocell-PD?

Neurocell-PD is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational therapy.

What phase is Neurocell-PD in?

Neurocell-PD is in Phase 2 clinical development. A Phase 2 trial has been completed, and the therapy remains investigational. It is not yet approved for commercial use, and further studies may be needed to establish its safety and effectiveness.

What clinical trials is Neurocell-PD in?

Neurocell-PD has been studied in one completed Phase 2 clinical trial, identified as NCT00226460. This was a double-blind, randomized, controlled multi-center trial conducted in the United States, evaluating the safety and efficacy of transplanted fetal porcine cells in patients with Parkinson's Disease.

Is Neurocell-PD the same as fetal porcine cells?

Neurocell-PD is a formulation of fetal porcine cells. The drug name refers to the specific therapeutic product being developed by Sanofi, which consists of these cells for transplantation in patients with Parkinson's Disease.